Captopril increases the intensity of monocyte infection by Trypanosoma cruzi and induces human T helper type 17 cells.
The anti-hypertensive drug captopril is used commonly to reduce blood pressure of patients with severe forms of Chagas disease, a cardiomyopathy caused by chronic infection with the intracellular protozoan Trypanosoma cruzi. Captopril acts by inhibiting angiotensin-converting enzyme (ACE), the vasopressor metallopeptidase that generates angiotensin II and promotes the degradation of bradykinin (BK). Recent studies in mice models of Chagas disease indicated that captopril can potentiate the T helper type 1 (Th1)-directing natural adjuvant property of BK. Equipped with kinin-releasing cysteine proteases, T. cruzi trypomastigotes were shown previously to invade non-professional phagocytic cells, such as human endothelial cells and murine cardiomyocytes, through the signalling of G protein-coupled bradykinin receptors (B(2) KR). Monocytes are also parasitized by T. cruzi and these cells are known to be important for the host immune response during infection. Here we showed that captopril increases the intensity of T. cruzi infection of human monocytes in vitro. The increased parasitism was accompanied by up-regulated expression of ACE in human monocytes. While T. cruzi infection increased the expression of interleukin (IL)-10 by monocytes significantly, compared to uninfected cells, T. cruzi infection in association with captopril down-modulated IL-10 expression by the monocytes. Surprisingly, studies with peripheral blood mononuclear cells revealed that addition of the ACE inhibitor in association with T. cruzi increased expression of IL-17 by CD4(+) T cells in a B(2) KR-dependent manner. Collectively, our results suggest that captopril might interfere with host-parasite equilibrium by enhancing infection of monocytes, decreasing the expression of the modulatory cytokine IL-10, while guiding development of the proinflammatory Th17 subset.
Coelho dos Santos
J S
JS
Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
Menezes
C A S
CA
Villani
F N A
FN
Magalhães
L M D
LM
Scharfstein
J
J
Gollob
K J
KJ
Dutra
W O
WO
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000469:parasitology / Q000473:pathology; D002216:Captopril / Q000494:pharmacology*; D002478:Cells, Cultured; D014355:Chagas Disease / Q000188:drug therapy* / Q000276:immunology / Q000469:parasitology / Q000503:physiopathology; D005786:Gene Expression Regulation; D006790:Host-Parasite Interactions / Q000187:drug effects; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D016753:Interleukin-10 / Q000096:biosynthesis / Q000235:genetics; D020381:Interleukin-17 / Q000235:genetics / Q000378:metabolism; D008297:Male; D009000:Monocytes / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000469:parasitology / Q000473:pathology; D012084:Renin-Angiotensin System / Q000187:drug effects; D058408:Th1-Th2 Balance; D014349:Trypanosoma cruzi / Q000276:immunology* / Q000472:pathogenicity; D014774:Virulence / Q000187:drug effects
D000806:Angiotensin-Converting Enzyme Inhibitors; D018836:Inflammation Mediators; D020381:Interleukin-17; D016753:Interleukin-10; D002216:Captopril